REFERENCES
- Bourgault C., et al. Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study—Observational (CALIPSO). Can. J. Cardiol 2005; 21: 1187–1193
- Breier A., Barancik M., Sulova Z., Uhrik B. P-glycoprotein—implications of metabolism of neoplastic cells and cancer therapy. Curr. Cancer Drug Targets 2005; 5: 457–468
- Chang, G. (2003). Multidrug resistance ABC transporters, FEBS Lett. 555, 102–105
- Chow C., Donovan L., Manuel D., Johansen H., Tu J. V. Regional variation in self-reported heart disease prevalence in Canada. Can. J. Cardiol 2005; 21: 1265–1271
- Drescher S., et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther 2003; 73: 223–231
- Field F. J., Born E., Murthy S., Mathur S. N. Transport of cholesterol from the endoplasmic reticulum to the plasma membrane is constitutive in CaCo-2 cells and differs from the transport of plasma membrane cholesterol to the endoplasmic reticulum. J. Lipid Res 1998; 39: 333–343
- Glavinas H., Krajcsi P., Cserepes J., Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug Deliv 2004; 1: 27–42
- Hoffmeyer S., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A 2000; 97: 3473–3478
- Hu C. C., Qing K., Chen Y. Diet-induced changes in stearoyl-CoA desaturase 1 expression in obesity-prone and -resistant mice. Obes. Res 2004; 12: 1264–1270
- Hui D. Y., Howles P. N. Molecular mechanisms of cholesterol absorption and transport in the intestine. Semin. Cell Dev. Biol 2005; 16: 183–192
- Kunta J. R., Sinko P. J. Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug Metab 2004; 5: 109–124
- Lam P., Wang R., Ling V. Bile Acid Transport in Sister of P-Glycoprotein (ABCB11) Knockout Mice. Biochemistry 2005; 44: 12598–12605
- Le Goff G. W., Settle M., Greene D. J., Morton R. E., Smith J. D. Reevaluation of the role of the multidrug resistant P-glycoprotein in cellular cholesterol homeostasis. J. Lipid Res 2005, Oct 7th, Epub
- Luker G. D., Dahlheimer J. L., Ostlund R. E., Jr., Piwnica-Worms D. Decreased hepatic accumulation and enhanced esterification of cholesterol in mice deficient in mdr1a and mdr1b P-glycoproteins. J. Lipid Res 2001; 42: 1389–1394
- Plosch T., et al. Mdr P-glycoproteins are not essential for biliary excretion of the hydrophobic heme precursor protoporphyrin in a griseofulvin-induced mouse model of erythropoietic protoporphyria. Hepatology 2002; 35: 299–306
- Rodrigues A. C., et al. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz. J. Med. Biol. Res 2005; 38: 1389–1397
- Tessner T. G., Stenson W. F. Overexpression of MDR1 in an intestinal cell line results in increased cholesterol uptake from micelles. Biochem. Biophys. Res. Commun 2000; 267: 565–571
- Tous M., et al. Turpentine-induced inflammation reduces the hepatic expression of the multiple drug resistance gene, the plasma cholesterol concentration and the development of atherosclerosis in apolipoprotein E deficient mice. Biochim. Biophys. Acta 2005; 1733: 192–198
- Turley S. D. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin. Cardiol 2004; 27(III)16–21
- Wang E., Casciano C. N., Clement R. P., Johnson W. W. Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem. Biophys. Res. Commun 2000; 276: 909–916